RNASE13

Summary

RNASE13 (ribonuclease A family member 13 (inactive), HGNC:25285) is a protein-coding gene on chromosome 14q11.1, encoding Probable inactive ribonuclease-like protein 13 (Q5GAN3). Does not exhibit any ribonuclease activity.

Predicted to enable nucleic acid binding activity. Predicted to be involved in defense response to Gram-positive bacterium. Predicted to be located in extracellular region.

Source: NCBI Gene 440163 — RefSeq curated summary.

At a glance

• MANE Select transcript: NM_001012264

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25285
Approved symbol	RNASE13
Name	ribonuclease A family member 13 (inactive)
Location	14q11.1
Locus type	gene with protein product
Status	Approved
Aliases	RAL1
Ensembl gene	ENSG00000206150
Ensembl biotype	protein_coding
Entrez	440163

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000382951

RefSeq mRNA: 1 — MANE Select: NM_001012264 NM_001012264

CCDS: CCDS32039

Canonical transcript exons

ENST00000382951 — 2 exons

Exon	Start	End
ENSE00001494024	21032818	21034296
ENSE00001494026	21034656	21034807

Expression profiles

Bgee: expression breadth broad, 68 present calls, max score 57.86.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0604 / max 108.0045, expressed in 1 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
142107	0.0268	1
142108	0.0209	1
142109	0.0106	1
142106	0.0020	1

Top tissues by expression

99 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	57.86	gold quality
mucosa of stomach	UBERON:0001199	54.91	gold quality
skeletal muscle tissue	UBERON:0001134	53.77	gold quality
liver	UBERON:0002107	53.35	gold quality
apex of heart	UBERON:0002098	50.51	gold quality
spleen	UBERON:0002106	49.17	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	48.69	gold quality
muscle tissue	UBERON:0002385	47.43	gold quality
body of pancreas	UBERON:0001150	47.35	gold quality
muscle of leg	UBERON:0001383	47.12	gold quality
gastrocnemius	UBERON:0001388	46.86	gold quality
right coronary artery	UBERON:0001625	46.60	gold quality
mucosa of transverse colon	UBERON:0004991	46.39	gold quality
saliva-secreting gland	UBERON:0001044	44.26	gold quality
heart left ventricle	UBERON:0002084	44.13	gold quality
sural nerve	UBERON:0015488	43.28	gold quality
granulocyte	CL:0000094	42.59	silver quality
right lung	UBERON:0002167	42.42	gold quality
left lobe of thyroid gland	UBERON:0001120	42.16	gold quality
subcutaneous adipose tissue	UBERON:0002190	42.12	gold quality
tibial artery	UBERON:0007610	42.03	gold quality
tibial nerve	UBERON:0001323	41.98	gold quality
colonic epithelium	UBERON:0000397	41.87	gold quality
minor salivary gland	UBERON:0001830	41.84	gold quality
thoracic mammary gland	UBERON:0005200	41.83	gold quality
popliteal artery	UBERON:0002250	41.80	gold quality
thyroid gland	UBERON:0002046	41.62	gold quality
adult mammalian kidney	UBERON:0000082	41.56	gold quality
right lobe of thyroid gland	UBERON:0001119	41.38	silver quality
pancreas	UBERON:0001264	41.23	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-HCAD-38	no	406.39
E-ANND-3	no	1.97

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

98 targeting RNASE13, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-6086	99.70	65.38	699
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-3679-3P	99.64	69.88	1599

Literature-anchored findings (GeneRIF, showing 1)

• rs1465567 of EGFLAM and rs113710653 of SPATC1L may be susceptibility loci for true aortic aneurysm and rs143881017 of RNASE13 may be such a locus for dissecting aortic aneurysm in Japanese individuals. (PMID:28339009)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Rnase13	ENSMUSG00000068392
rattus_norvegicus	Rnase13	ENSRNOG00000039500

Paralogs (12): RNASE1 (ENSG00000129538), RNASE7 (ENSG00000165799), RNASE2 (ENSG00000169385), RNASE3 (ENSG00000169397), RNASE6 (ENSG00000169413), RNASE8 (ENSG00000173431), RNASE11 (ENSG00000173464), RNASE10 (ENSG00000182545), RNASE9 (ENSG00000188655), ANG (ENSG00000214274), RNASE12 (ENSG00000258436), RNASE4 (ENSG00000258818)

Protein

Protein identifiers

Probable inactive ribonuclease-like protein 13 — Q5GAN3 (reviewed: Q5GAN3)

All UniProt accessions (2): Q5GAN3, V9HW52

UniProt curated annotations — full annotation on UniProt →

Function. Does not exhibit any ribonuclease activity.

Subcellular location. Secreted.

Similarity. Belongs to the pancreatic ribonuclease family.

RefSeq proteins (1): NP_001012264* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001427	RNaseA	Family
IPR023412	RNaseA_domain	Domain
IPR036816	RNaseA-like_dom_sf	Homologous_superfamily

Pfam: PF00074

UniProt features (4 total): signal peptide 1, chain 1, glycosylation site 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5GAN3-F1	89.70	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (1): 126

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 35 (showing top): GOMF_RNA_NUCLEASE_ACTIVITY, GOMF_NUCLEASE_ACTIVITY, GOBP_DEFENSE_RESPONSE_TO_GRAM_POSITIVE_BACTERIUM, GOBP_DEFENSE_RESPONSE_TO_BACTERIUM, GOBP_RESPONSE_TO_BACTERIUM, MARTENS_TRETINOIN_RESPONSE_DN, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, GOMF_CATALYTIC_ACTIVITY_ACTING_ON_RNA, MIR6825_5P, MIR4447, MIR6756_5P, MIR4723_5P, MIR6766_5P, MIR8085, MIR6731_5P

GO Biological Process (1): defense response to Gram-positive bacterium (GO:0050830)

GO Molecular Function (1): nucleic acid binding (GO:0003676)

GO Cellular Component (1): extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
defense response to bacterium	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

244 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RNASE13	RALA	P11233	571
RNASE13	PATE3	B3GLJ2	546
RNASE13	PATE2	Q6UY27	508
RNASE13	RNASE11	Q8TAA1	507
RNASE13	PATE1	Q8WXA2	495
RNASE13	RNASE8	Q8TDE3	483
RNASE13	WFDC9	Q8NEX5	479
RNASE13	RAB27B	O00194	473
RNASE13	RNASE12	Q5GAN4	461
RNASE13	WFDC13	Q8IUB5	452
RNASE13	RAB27A	P51159	447
RNASE13	INTS10	Q9NVR2	440
RNASE13	RAB35	Q15286	434
RNASE13	EXOC8	Q8IYI6	433
RNASE13	RNASE3	P12724	426

IntAct

3 interactions, top by confidence:

A	B	Type	Score
RNASE13	APOD	psi-mi:“MI:0914”(association)	0.530
RNASE13	POTEF	psi-mi:“MI:0914”(association)	0.350

BioGRID (25): CACNA2D2 (Affinity Capture-MS), CLCC1 (Affinity Capture-MS), COL14A1 (Affinity Capture-MS), MUCL1 (Affinity Capture-MS), SUSD1 (Affinity Capture-MS), LRP2 (Affinity Capture-MS), CLU (Affinity Capture-MS), PPM1A (Affinity Capture-MS), CPE (Affinity Capture-MS), CD109 (Affinity Capture-MS), PPM1A (Affinity Capture-MS), SUSD1 (Affinity Capture-MS), CPE (Affinity Capture-MS), COL14A1 (Affinity Capture-MS), APOD (Affinity Capture-MS)

ESM2 similar proteins: A5HAK0, O18937, O35290, O35291, O35292, P00686, P10153, P11916, P12724, P27043, P30374, P47778, P47779, P47780, P47781, P47782, P47783, P47784, P47785, P47786, P70709, P97425, P97426, Q5GAL7, Q5GAM7, Q5GAN3, Q8SPY2, Q8SPY3, Q8SPY4, Q8SPY5, Q8SPY6, Q8SPY7, Q8SPY8, Q8SPY9, Q8VD84, Q8VD85, Q8VD86, Q8VD87, Q8VD88, Q8VD89

Diamond homologs: Q5GAL7, Q5GAM7, Q5GAN3, P80287

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

221 predictions. Top by Δscore:

Variant	Effect	Δscore
14:21034651:CTGA:C	donor_loss	0.9100
14:21034652:TGA:T	donor_loss	0.9100
14:21034653:GA:G	donor_loss	0.9100
14:21034654:ACCT:A	donor_loss	0.9100
14:21034655:CCTG:C	donor_loss	0.9100
14:21034650:GCTGA:G	donor_loss	0.9000
14:21034656:C:G	donor_loss	0.8500
14:21034249:CAAG:C	acceptor_gain	0.8400
14:21033959:C:CT	acceptor_gain	0.7200
14:21034290:CCTC:C	acceptor_gain	0.7100
14:21034291:CTCC:C	acceptor_gain	0.7100
14:21034292:TCCT:T	acceptor_gain	0.7100
14:21034253:C:CC	acceptor_gain	0.5900
14:21034649:GGCT:G	donor_loss	0.5700
14:21033125:C:CC	acceptor_gain	0.5300
14:21034298:T:G	acceptor_gain	0.5200
14:21034446:G:A	donor_gain	0.5100
14:21034657:T:G	donor_loss	0.5000
14:21033068:TCTGG:T	acceptor_gain	0.4900
14:21034252:G:C	acceptor_gain	0.4900
14:21034297:C:T	acceptor_gain	0.4900
14:21034256:G:GA	acceptor_gain	0.4800
14:21034257:A:AA	acceptor_gain	0.4800
14:21033069:C:G	acceptor_gain	0.4700
14:21033124:A:AC	acceptor_gain	0.4700
14:21034264:G:GA	acceptor_gain	0.4700
14:21034400:T:TA	donor_gain	0.4600
14:21034648:AGGC:A	donor_loss	0.4600
14:21034492:C:A	donor_gain	0.4500
14:21034654:A:AC	donor_gain	0.4500

AlphaMissense

1029 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:21033954:C:G	C112S	0.990
14:21033955:A:T	C112S	0.990
14:21033876:C:G	C138S	0.984
14:21033877:A:T	C138S	0.984
14:21033955:A:G	C112R	0.984
14:21034032:C:T	C86Y	0.984
14:21034134:C:T	C52Y	0.984
14:21034032:C:G	C86S	0.983
14:21034033:A:T	C86S	0.983
14:21034134:C:G	C52S	0.982
14:21034135:A:T	C52S	0.982
14:21033954:C:T	C112Y	0.977
14:21034031:G:C	C86W	0.975
14:21034134:C:A	C52F	0.975
14:21034086:C:G	C68S	0.974
14:21034087:A:T	C68S	0.974
14:21034145:G:C	F48L	0.974
14:21034145:G:T	F48L	0.974
14:21034147:A:G	F48L	0.974
14:21033953:G:C	C112W	0.973
14:21033990:C:G	C100S	0.972
14:21033991:A:T	C100S	0.972
14:21033877:A:G	C138R	0.970
14:21034013:G:C	F92L	0.970
14:21034013:G:T	F92L	0.970
14:21034015:A:G	F92L	0.970
14:21034133:A:C	C52W	0.970
14:21033875:G:C	C138W	0.969
14:21033876:C:T	C138Y	0.969
14:21033921:C:G	C123S	0.969

dbSNP variants (sampled 300 via entrez): RS1000119394 (14:21032810 G>A), RS1002122201 (14:21035193 T>C), RS1002168055 (14:21034465 A>ACCAG), RS1004138491 (14:21036382 A>G), RS1004348905 (14:21032450 G>A,T), RS1005486927 (14:21033360 T>A,C), RS1006449318 (14:21033423 G>T), RS1006541512 (14:21032670 C>G,T), RS1007358651 (14:21036194 A>G,T), RS1008551017 (14:21035101 G>A), RS1008936341 (14:21035406 G>C), RS1009843769 (14:21032830 A>G), RS1010030466 (14:21035788 A>G), RS1012422381 (14:21036750 G>A), RS1012439478 (14:21036527 C>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

4 total (human), top 4 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Resveratrol	affects cotreatment, decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Plant Extracts	decreases expression, affects cotreatment	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.